前列腺癌和前列腺增生鉴别诊断中游离PSA/PSA比值的临床评价

Clinical Evaluation of FPSA/PSA Ratio in the Differential Diagnosis of Prostate Carcinoma and Benign Prostate Hyperplasia

目的 探讨游离PSA(FPSA) /PSA比值在前列腺癌 (Pca)和前列腺增生 (BPH)的鉴别诊断中的临床意义。方法 回顾5 2例Pca和BPH病例 (其血PSA值均在 5～ 2 0ng/ml)的FPSA值 ,并求出FPSA/PSA比值。结果 Pca和BPH各自的FPSA/PSA比值有显著的差异。 (t =4 0 1,P <0 0 1)。结论 FPSA/PSA比值可用于鉴别Pca和BPH。

Objective To explore the clinical significance of FPSA/PSA ratio in the differential diagnosis of prostate carcinoma(Pca) and benign prostate hyperplasia (BPH). Methods The concentrations of FPSA and PSA in 52 patients with Pca or BPH were analysed retrospectively to calculate FPSA/PSA ratio. Results FPSA/PSA ratio between the Pca and BPH was markedly different (t=4 01,P<0 001). Conclusion FPSA/PSA ratio can be used to differentially diagnose Pca and BPH.